menu
    • menu

    Company profile for Biohaven Pharmaceuticals

    NEW Drugs in Dev: 18
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The most advanced product candidate from our CGRP receptor antagonist platform is rimegepant. The most advanced product candidate from our glutamate modulation platform is trigriluzole, which we are developing for the treatment of ataxias with an initial focus on spinocerebellar ataxia, or SCA. We have rece...
    Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The most advanced product candidate from our CGRP receptor antagonist platform is rimegepant. The most advanced product candidate from our glutamate modulation platform is trigriluzole, which we are developing for the treatment of ataxias with an initial focus on spinocerebellar ataxia, or SCA. We have received orphan drug designation from the FDA for trigriluzole in SCA, and we began a Phase 2/3 clinical trial in SCA in December 2016 and expect to report topline results in early 2018.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Biohaven PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Biohaven Pharmaceuticals, Inc 234 Church Street New Haven, CT 06510
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biohavenpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biohaven-pharmaceuticals-inc/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/biohavenpharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biohaven Reports Q1 2026 Results and Recent Business Updates
    Biohaven Reports Q1 2026 Results and Recent Business Updates

    05 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-reports-recent-business-developments-and-first-quarter-2026-financial-results-302761656.html

    PR NEWSWIRE
    05 May 2026
    Share Share
    Biohaven Completes Phase 2 Taldefgrobep Alfa Obesity Trial
    Biohaven Completes Phase 2 Taldefgrobep Alfa Obesity Trial

    19 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohavens-phase-2-obesity-study-with-taldefgrobep-alfa-a-novel-myostatin-activin-pathway-inhibitor-completes-enrollment-302718076.html

    PR NEWSWIRE
    19 Mar 2026
    Share Share
    Biohaven Reduces Scope Of R&D Cuts As Pipeline Progresses
    Biohaven Reduces Scope Of R&D Cuts As Pipeline Progresses

    03 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/biohaven-pushes-ahead-rd-cutbacks-timeline-doubt

    FIERCE BIOTECH
    03 Mar 2026
    Share Share
    Biohaven CEO Calls Recent FDA Decisions 'A Systemic Problem'
    Biohaven CEO Calls Recent FDA Decisions 'A Systemic Problem'

    13 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/its-really-dire-time-patients-biohaven-ceo-says-fda-red-tape-blocking-access-rare-disease

    FIERCE BIOTECH
    13 Feb 2026
    Share Share
    Biohaven Prepares To Challenge Lilly After Tough 2025
    Biohaven Prepares To Challenge Lilly After Tough 2025

    20 Jan 2026

    // BIOSPACE

    https://www.biospace.com/business/jpm26-after-a-tough-2025-biohaven-is-gearing-up-to-challenge-goliath-lilly

    BIOSPACE
    20 Jan 2026
    Share Share
    Biohaven Showcases Advances In Degrader Programs At J.P. Morgan
    Biohaven Showcases Advances In Degrader Programs At J.P. Morgan

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-highlights-portfolio-progress-positive-early-patient-data-from-priority-degrader-programs-and-anticipated-milestones-at-the-44th-annual-jp-morgan-healthcare-conference-302658655.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search